soluble [celc]
Urokinase Plasminogen Activator Receptor [aapp, rcpt]
Prognostic Marker [qlco]
Men [popg]
Participating [ftcn]
prostate cancer screening [topp]
H+ [elii]
Circle [spco]
Divide [ftcn]
g% [qnco]
H+ [elii]
M NOS [aapp, imft]
Department [orgt]
Clinical [qlco]
Science [ocdi]
intervention [hlca]
Technology [ocdi]
Clinical Unit [qnco]
Epidemiology [bmod]
Department [orgt]
Medicine [phsu]
Sweden [geoa]
Laboratory [mnob, orgt]
Denmark [geoa]
Department [orgt]
Clinical [qlco]
Laboratories [mnob, orgt]
Urology [bmod]
Medicine [phsu]
Memorial Sloan-Kettering Cancer Center [hcro]
New York [geoa]
NY [geoa]
USA [geoa]
Department [orgt]
Clinical [qlco]
Science [ocdi]
Education [edac]
Sweden [geoa]
Syrinx [anab]
Finland [geoa]
FORMERLY [gngm]
Laboratory [mnob, orgt]
Denmark [geoa]
soluble [celc]
Urokinase Plasminogen Activator Receptor [aapp, rcpt]
Prognostic Marker [qlco]
Men [popg]
Participating [ftcn]
prostate cancer screening [topp]
INTERN [prog]
Background [cnce]
Plasminogen Activator, Urokinase [aapp, enzy, phsu]
System [ftcn]
Involved [ftcn]
tissue remodeling [biof]
Process [bpoc]
Up [spco]
Regulated [gora]
Types [qlco]
malignancies [neop]
investigated [ftcn]
Serum [bdsu]
Level [qlco]
Different [qlco]
forms [qlco]
soluble [celc]
Urokinase Plasminogen Activator Receptor [aapp, rcpt]
Associated [qlco]
Survival [acty]
Prostate Cancer [neop]
Cardiovascular disease [dsyn]
Mortality [qnco]
Methods [inpr]
Using [ftcn]
Time resolved fluorescence immunoassay [lbpr]
Measured [qlco]
Intact [qlco]
soluble [celc]
U-PA Receptor [aapp, rcpt]
soluble [celc]
U-PA Receptor [aapp, rcpt]
I- [inch]
III [inpr]
Intact [qlco]
Plus [qlco]
Cleaved [spco]
soluble [celc]
U-PA Receptor [aapp, rcpt]
soluble [celc]
U-PA Receptor [aapp, rcpt]
I- [inch]
III [inpr]
soluble [celc]
U-PA Receptor [aapp, rcpt]
Ii [aapp]
III [inpr]
Calculated [ftcn]
Amount [qnco]
soluble [celc]
U-PA Receptor [aapp, rcpt]
Ii [aapp]
III [inpr]
Serum sample [bdsu]
Men [popg]
Participating [ftcn]
prostate cancer screening [topp]
Trial [resa]
Men [popg]
free [ftcn]
Prostate Cancer [neop]
Men [popg]
Prostate Cancer [neop]
Diagnosed [fndg]
Time [tmco]
Screening [hlca]
Cohort [popg]
Assessed [acty]
Survival [acty]
Using [ftcn]
estimation [menp]
Proportional [qlco]
Hazard [qlco]
Regression [patf]
Result [ftcn]
Mean [qnco]
Age [orga]
Blood sampling [diap]
Men [popg]
Died [orgf]
Follow-up [fndg]
I- [inch]
III [inpr]
soluble [celc]
U-PA Receptor [aapp, rcpt]
Ii [aapp]
III [inpr]
Associated [qlco]
Mortality [qnco]
P NOS [aapp, imft]
P NOS [aapp, imft]
Regression [patf]
Model [inpr]
Age [orga]
Prostate Cancer [neop]
Status [qlco]
Increase [ftcn]
soluble [celc]
U-PA Receptor [aapp, rcpt]
I- [inch]
III [inpr]
soluble [celc]
U-PA Receptor [aapp, rcpt]
Ii [aapp]
III [inpr]
Unit [qnco]
LN [neop]
Scale [medd]
Associated [qlco]
Hazard Ratio [qnco]
Confidence Interval [qnco]
Confidence Interval [qnco]
trend [tmco]
Increased [qnco]
Risk [qlco]
Death [orgf]
Prostate Cancer [neop]
screening cancer [diap]
Detected [fndg]
Prostate [bpoc]
Patients [podg]
Increased [qnco]
Values [qlco]
soluble [celc]
U-PA Receptor [aapp, rcpt]
Form [qlco]
Not significant [fndg]
Association [menp]
Age [orga]
Tumor stage [clna]
Tumor [neop]
Grade [clas]
Prostate-Specific Antigen [aapp, enzy, imft]
Highest [qlco]
Quartile [qlco]
soluble [celc]
U-PA Receptor [aapp, rcpt]
forms [qlco]
Associated [qlco]
Highly significant [qlco]
Increased [qnco]
Risk [qlco]
CARDIOVASCULAR [bdsy]
Death [orgf]
Hazard Ratio [qnco]
Adjusted [ftcn]
Age [orga]
Confidence Interval [qnco]
soluble [celc]
U-PA Receptor [aapp, rcpt]
I- [inch]
III [inpr]
Quartile [qlco]
Quartile [qlco]
Conclusions [idcn]
High [qlco]
Concentrations [menp]
Serum [bdsu]
soluble [celc]
U-PA Receptor [aapp, rcpt]
I- [inch]
III [inpr]
soluble [celc]
U-PA Receptor [aapp, rcpt]
Ii [aapp]
III [inpr]
Associated [qlco]
Poor [grpa]
Overall [inpr]
Survival [acty]
Association [menp]
Strong [qlco]
Death [orgf]
Cardiovascular disease [dsyn]
Similar [qlco]
Association [menp]
Found [qnco]
Prostate Cancer [neop]
Adjustment [inbe]
Prognostic Factor [clna]
